World's Best Scientists 2026 revealed!
Oncologist
H-index 55

Oncologist

1083-7159

Published by: AlphaMed Press

https://alphamedpress.com/the-oncologist

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Medicine 199 800 877 53

Additional Metrics

Number of Best Scientists*: 992
Documents by Best Scientists*: 986
Top 100 Ranked Scientists*: 21
SCIMAGO H-index: 199
SCIMAGO SJR: 2.329
Impact Factor: 4.2

Overview

Top Research Topics at Oncologist?

The topics of Internal medicine, Oncology, Cancer, Chemotherapy and Breast cancer are the focal point of discussions in Oncologist. In addition to Internal medicine research, Oncologist aims to explore topics under Gastroenterology and Surgery. The Oncology works featured in the journal incorporate elements from Radiation therapy, Regimen, Colorectal cancer and Disease.

The studies on Cancer discussed can also contribute to research in the domains of Family medicine, MEDLINE and Intensive care medicine. Oncologist facilitated presentations on Breast cancer research, particularly Metastatic breast cancer and Trastuzumab. Hazard ratio studies tackled cover an aspect of the field of Confidence interval.

Studies on Clinical trial discussed in the journal link to the field of Randomized controlled trial.

  • Internal medicine (56.47%)
  • Oncology (42.89%)
  • Cancer (22.65%)

What are the most cited papers published in the journal?

  • SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer. (1583 citations)
  • Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition (970 citations)
  • FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma (919 citations)

Research areas of the most cited articles at Oncologist:

The most cited articles primarily focus on research topics in Internal medicine, Oncology, Cancer, Chemotherapy and Surgery. Internal medicine research in the most cited articles connects with the study of Gastroenterology. While Oncology is the focus of the journal articles, it also provides insights into the studies of Metastatic breast cancer, Docetaxel, Colorectal cancer, Radiation therapy and Pharmacology.

What topics the last edition of the journal is best known for?

  • Cancer
  • Internal medicine
  • Disease

The previous edition focused in particular on these issues:

The journal explores disciplines such as Internal medicine, Oncology, Cancer, Adverse effect and Clinical trial. The study on Internal medicine presented in Oncologist intersects with subjects under the field of Gastroenterology. Pembrolizumab, Retrospective cohort study, Proportional hazards model, Disease and Breast cancer are some topics wherein Oncology research discussed in the journal have an impact.

While Cancer is the key highlight in Oncologist, it also covered some subjects on Intensive care medicine and Quality of life (healthcare). The research on Adverse effect tackled can also make contributions to studies in the areas of Pharmacokinetics, Discontinuation, Phases of clinical research, Neutropenia and Nausea. The studies tackled, which mainly focus on Clinical trial, apply to Randomized controlled trial as well.

The most cited articles from the last journal are:

  • FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer. (12 citations)
  • Cancer in Lockdown: Impact of the COVID-19 Pandemic on Patients with Cancer. (11 citations)
  • Update on Guidelines for the Management of Cancer-Associated Thrombosis. (10 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Oncologist (based on the number of publications) are:

  • Bruce A. Chabner (118 papers) published 3 papers at the last edition, 5 less than at the previous edition,
  • Richard Pazdur (64 papers) absent at the last edition,
  • Eduardo Bruera (48 papers) published 7 papers at the last edition, 4 more than at the previous edition,
  • Gabriel N. Hortobagyi (46 papers) absent at the last edition,
  • Thomas J. Lynch (38 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Oncologist (based on the number of publications) are:

  • Harvard University (551 papers) published 63 papers at the last edition, 14 more than at the previous edition,
  • University of Texas MD Anderson Cancer Center (329 papers) published 35 papers at the last edition, 2 more than at the previous edition,
  • Memorial Sloan Kettering Cancer Center (205 papers) published 21 papers at the last edition, 4 more than at the previous edition,
  • Mayo Clinic (130 papers) published 19 papers at the last edition, 4 more than at the previous edition,
  • University of North Carolina at Chapel Hill (95 papers) published 6 papers at the last edition, 2 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 5.19% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 36.57% were posted by at least one author from the top 10 institutions publishing in the journal. Another 11.94% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 14.43% of all publications and 37.06% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Role of Nurse Practitioners in Oncology Care

Nurse practitioners (NPs) play an essential role in Oncology care, contributing to both research and practical application. They provide an array of services from prevention to screening and from diagnosis to treatments. NPs are particularly crucial in providing personalized care in oncology, guiding patients through complex medical terminology, treatment options, and potential side effects. Further, they conduct research to support improving patient outcomes and contribute substantively to the multidisciplinary oncology team. To become a nurse practitioner in oncology, one needs extensive training and education. One must first achieve their registered nurse license, followed by further studies specializing in oncology. The path to becoming a nurse practitioner might differ based on locations, if you are interested in practicing in North Dakota, you can follow the guide on how to become a nurse practitioner in North Dakota. This represents yet another essential relationship between research and practical care, as the education and preparation of NPs involve both classroom learning and practical hands-on experience. In conclusion, nurse practitioners form a core part of the oncology team, providing essential care services and contributing to the breadth and depth of oncology research.

Top Publications

  • A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.

    Humaid O. Al-Shamsi;Waleed Alhazzani;Ahmad Alhuraiji;Eric A. Coomes

    (2020)
    722 Citations
  • Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence

    Samuel J. Klempner;David Fabrizio;Shalmali Bane;Marcia Reinhart

    (2020)
    298 Citations
  • The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry.

    Olga Husson;Belle H de Rooij;Jacobien Kieffer;Simone Oerlemans

    (2020)
    169 Citations
  • Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.

    Suneel D. Kamath;Aparna Kalyan;Sheetal Kircher;Halla Nimeiri

    (2020)
    164 Citations
  • Survivorship Care Plans in Cancer: A Meta-Analysis and Systematic Review of Care Plan Outcomes

    Rebecca E. Hill;Rebecca E. Hill;Claire E. Wakefield;Claire E. Wakefield;Richard J. Cohn;Richard J. Cohn;Joanna E. Fardell;Joanna E. Fardell

    (2020)
    163 Citations
  • Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer

    Nadina Tinsley;Cong Zhou;Grace Tan;Samuel Rack

    (2020)
    145 Citations
  • Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?

    Alice Avancini;Giulia Sartori;Anastasios Gkountakos;Miriam Casali

    (2020)
    135 Citations
  • Homologous Recombination Deficiency: Concepts, Definitions, and Assays

    (2022)
    134 Citations
  • Associations of Polypharmacy and Inappropriate Medications with Adverse Outcomes in Older Adults with Cancer: A Systematic Review and Meta-Analysis

    Mostafa R. Mohamed;Erika Ramsdale;Kah Poh Loh;Asad Arastu

    (2020)
    127 Citations
  • Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial.

    Weidong Lu;Anita Giobbie‐Hurder;Rachel A. Freedman;Im Hee Shin

    (2020)
    124 Citations

Related Online Degrees & Career Pathways

For those interested in expanding their healthcare expertise beyond medicine, several online degree options offer flexible and accelerated pathways. One promising route is enrolling in a fast track mental health nursing program. This allows students to quickly gain specialized skills to support mental health patients, addressing a critical need in healthcare.

Nutrition also plays a vital role in patient care and wellness. Prospective students can pursue a fast track nutrition degree online, enabling them to enter the field rapidly and make an impact in dietetics and community health services.

For those inclined towards leadership and management within healthcare settings, earning an affordable online MBA healthcare management degree provides essential business acumen. This degree equips professionals to navigate complexities in hospital administration, policy, and health services management.

Additionally, individuals without a nursing background can transition into the nursing profession through a non nursing degree to BSN online program. This accelerated path opens doors to nursing careers efficiently, combining flexibility with robust clinical preparation.

Best Scientists Contributing to This Journal

Recently Published Articles